ARCHIVES

FDA Committee Okays Leuprolide NDA, But Recommends Against Mitoxantrne, Epirubicin

This article is from The Cancer Letter archive.

Vol. 11 No. 14 | April 5, 1985

Download PDF Visit The Full Archive

Related Articles

NCI STRAP Grants Aim To Move Research Quickly To Clinical Trials

October 1, 2010

ASCO Backs Central IRB For Cancer Trials, Stiffens Conflict-of-Interest Policies

May 2, 2003

DCPC Planning 10 More Prevention Fellowship Awards

August 14, 1987

Health Canada Suspends Avastin Approval; CMS Has Taken No Action After FDA Decision

December 2, 2011

NCI Considering Adoption Of NIGMS Guidelines To Limit Growth Of Renewals, Ensure New Grants

November 30, 1990

Tobacco Control: Cigarette Consumption In ASSIST States 10% Below Other States

January 17, 1997